Tyra Biosciences, Inc. Share Price & Technical Analysis
TYRA · $33.51 (+3.20%)
Healthcare / Biotechnology
$33.51
+3.20%
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-7% return in May, -5% avg return in past 3 year May month.
28% return in 2026, 70% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 17% | 9% | 20% | -11% | -7% | – | – | – | – | – | – | – | 28% |
| 25 | 3% | -18% | -21% | 12% | -12% | 4% | 15% | 18% | 11% | 14% | 44% | 26% | 96% |
| 24 | -1% | 55% | -18% | 4% | -5% | -2% | 39% | 4% | 3% | -29% | -6% | -11% | 32% |
| 23 | 38% | 25% | 20% | -11% | 3% | 21% | -13% | 3% | -11% | -15% | 2% | 20% | 81% |
| 22 | -8% | -10% | -9% | -32% | -8% | 4% | 56% | -35% | 31% | -22% | -1% | 7% | -27% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.01B
P/E ratio
—
52W high
$40.65
52W low
$8.75
Volume
4,05,781
Beta
0.79
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Tyra Biosciences, Inc. share price today?
- Tyra Biosciences, Inc. (TYRA) last traded around $33.51 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TYRA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TYRA. Download the app for real-time alerts.
- How can I analyze Tyra Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.